P108 Visilizumab Therapy in Subjects With Moderate-to-Severe, Refractory Crohn's Disease

Hommes, Daan W.; Targan, Stephan; Dignaß, Axel; Baumgart, DC; Mayer, Lloyd; Zhang, L.; Wilson, Kavitha; Pearce, Tillman

doi:10.1016/s1873-9954(07)70120-9

Search citation statements

Order By: Relevance

Paper Sections

Select...

Drugs Targeting Leucocyte Homing1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2016

Publication Types

Select...

Other1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other molecules targeting T cells, but not interfering with homing, have been studied with less success. Visilizumab, a humanized monoclonal antibody directed at the cell surface marker CD3 expressed only by activated T cells, inducing selective apoptosis of these activated T cells, has shown some efficacy in an uncontrolled trial [43] but was associated with an increased rate of adverse events, including cytokine release syndrome and liver toxicity [44].…”

Section: Drugs Targeting Leucocyte Homingmentioning

confidence: 99%

The role of mesenchymal stromal cells in the treatment of ulcerative colitis andCrohn's disease

Gregoire

Lechanteur

Briquet

et al. 2016

The Biology and Therapeutic Application of Mesenchymal Cells

View full text Add to dashboard Cite

Differentiation and stimulation of tissue repair, 740 50.6 Mesenchymal stromal cell administration in inflammatory bowel diseases, 740 50.6.1 Mesenchymal stromal cell administration for fistulizing Crohn's disease, 741 50.6.2 Autologous mesenchymal stromal cell administration for fistulizing Crohn's disease, 741 50.1 Inflammatory bowel diseases Inflammatory bowel diseases (IBDs) are chronic relapsing dis eases associated with debilitating symptoms and leading to progressive intestinal tissue damage and disability (Figure 50.1). Crohn's disease (CD) can affect any part of the gastrointestinal tract, and lesions are often segmental and transmural. The disease was named after gastroenterologist Dr Burrill Bernard

show abstract

Section: Drugs Targeting Leucocyte Homingmentioning

confidence: 99%